A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.

Cornered in a part of Downtown Los Angeles swamped in contemporary art museums and performance centers, REDCAT has become a ...

Since the 2000s, Google Search—and later YouTube and Discover—served as the primary discovery and monetization engines for digital publishing. This relationship was symbiotic, if lopsided. Two decades ...

The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for the next decade.

The lack of gains in productivity from AI could stall adoption and burst the economic bubble. Is there a rational explanation?

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Fruchter, G. (2026) Opportunism in Supply Chain Recommendations: A Dynamic Optimization Approach. Modern Economy, 17, 26-38.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...